NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Damora Therapeutics, Inc. (DMRA) Stock Analysis

Damora Therapeutics, Inc. (DMRA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

DMRA

$21.53

+$0.86 (+4.16%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DMRA with… →

DMRA Key Statistics

As of Oct 21, 2026
Trading
Open
$20.88
Previous Close
$20.67
Day's Range
20.66–22.68
52-Week Range
4.95–38.33
Volume
683.09K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.44
Valuation
Market Cap
$1.33B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.25
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$209.84M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
61.74M
1-Year Return
+152.40%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
525.12K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, DMRA closed at $21.53, +152.40% over 1 year.

Damora Therapeutics, Inc. (DMRA) has a market capitalization of $1.33B.

In fiscal 2025, DMRA reported revenue of $0.00.

DMRA Stock Return by Calendar Year

Damora Therapeutics, Inc. (DMRA) return since Oct 2020: what $10,000 became

1 year
$10,000 $25,240
+152.40%
5 years
$10,000 $2,454
−75.46%
Since Oct 2020
$10,000 $574
−94.26%

If you had invested $10,000 in Damora Therapeutics, Inc. (DMRA) at the close on October 29, 2020, the earliest close on record here, it would have been worth $574 at the close on October 21, 2026: −94.26% in total, −38.00% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−6.43%
2025+394.84%
2024−74.17%
2023−37.39%
2022−62.05%
2021−75.78%
2020 (partial year)−16.60%

As of October 21, 2026.

DMRA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$209.84M—
2024$0.00−$21.44M—
2023$0.00−$38.35M—
2022$0.00−$61.62M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$210.87M−$209.84M—
2024$0.00—−$21.29M−$21.44M—
2023$0.00—−$36.46M−$38.35M—
2022$0.00—−$61.21M−$61.62M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Damora Therapeutics, Inc. (DMRA) is capitalised at $1.33B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 7.

Over the past 52 weeks the price has ranged from $4.95 to $38.33. The most recent close on file for DMRA is $21.53, dated October 21, 2026. That is +$0.86 (+4.16%) against the previous close. The latest close sits 334.95% above that 52-week low.

Financial Health

In fiscal 2025, Damora Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $209.84M. Trailing earnings per share are −0.25.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 1.44. Annualized volatility over the trailing 6 years is 213.09%. The trailing one-year total return is +152.40%. Across 5 years the annualized return works out at −24.50%.

Growth & Income

The record shows no dividend for DMRA.

2026 is still running; the total return is −6.43% year to date. Across the complete calendar years on file, 2025 returned +394.84% and 2021 returned −75.78%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

Damora Therapeutics, Inc. (DMRA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Damora Therapeutics, Inc. DMRA $1.33B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Damora Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Damora Therapeutics, Inc.

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Visit website →